Johnson & Johnson
Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.
JNJ Key Statistics
Stock Snapshot
Johnson & Johnson(JNJ) stock is priced at $242.27, giving the company a market capitalization of 583.85B. It carries a P/E multiple of 22.02 and pays a dividend yield of 2.1%.
During the trading session on 2026-03-12, Johnson & Johnson(JNJ) shares reached a daily high of $244.00 and a low of $240.30. At a current price of $242.27, the stock is +0.8% higher than the low and still -0.7% under the high.
Trading volume for Johnson & Johnson(JNJ) stock has reached 1.58M, versus its average volume of 8.31M.
The stock's 52-week range extends from a low of $141.50 to a high of $251.71.
The stock's 52-week range extends from a low of $141.50 to a high of $251.71.
JNJ News
Johnson & Johnson (JNJ) announced on Thursday that the U.S. Food and Drug Administration (FDA) approved its Tecnis PureSee intraocular lens (IOL), giving eye su...
Johnson & Johnson announced FDA approval of Tecnis PureSee IOL, an extended depth of focus intraocular lens intended for use in cataract surgery. Tecnis PureSee...
Earlier this month, Johnson & Johnson received U.S. FDA approval for TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO for adults with relapsed or refractory mul...
Analyst ratings
55%
of 29 ratingsMore JNJ News
Success in business is challenging. Most new ventures don't last more than a decade. A few select companies survive and thrive for several decades. Fewer still...
Citi raised the firm’s price target on Johnson & Johnson to $274 from $250 and keeps a Buy rating on the shares. The firm adjusted targets in the medical techno...
Johnson & Johnson (JNJ) just secured U.S. FDA approval for TECVAYLI plus DARZALEX FASPRO in adults with relapsed or refractory multiple myeloma after at least o...
Johnson & Johnson’s Janssen Research & Development was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s w...
Johnson & Johnson (NYSE:JNJ) received FDA approval for TECVAYLI (teclistamab-cqyv) plus DARZALEX FASPRO as a treatment option for relapsed or refractory multipl...
On Thursday, the U.S. Food and Drug Administration approved Johnson & Johnson‘s (NYSE:JNJ) Tecvayli in combination with Darzalex Faspro for patients with relaps...
The latest announcement is out from Contineum Therapeutics, Inc. Class A ( (CTNM) ). Contineum Therapeutics amended its existing at-the-market equity program w...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.